MetLife Investment Management’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $448K | Buy |
29,918
+6,185
| +26% | +$92.6K | ﹤0.01% | 1732 |
|
|
2025
Q1 | $383K | Buy |
23,733
+2,351
| +11% | +$37.9K | ﹤0.01% | 1859 |
|
|
2024
Q4 | $498K | Buy |
21,382
+1,250
| +6% | +$29.1K | ﹤0.01% | 1799 |
|
|
2024
Q3 | $592K | Buy |
20,132
+11,344
| +129% | +$334K | ﹤0.01% | 1686 |
|
|
2024
Q2 | $207K | Buy |
+8,788
| New | +$207K | ﹤0.01% | 2224 |
|
|
2021
Q4 | – | Sell |
-614
| Closed | -$122K | – | 2551 |
|
|
2021
Q3 | $122K | Buy |
+614
| New | +$122K | ﹤0.01% | 2351 |
|
|
2021
Q2 | – | Sell |
-811
| Closed | -$161K | – | 2484 |
|
|
2021
Q1 | $161K | Buy |
811
+491
| +153% | +$97.3K | ﹤0.01% | 2162 |
|
|
2020
Q4 | $62.9K | Sell |
320
-485
| -60% | -$95.3K | ﹤0.01% | 2247 |
|
|
2020
Q3 | $143K | Hold |
805
| – | – | ﹤0.01% | 2049 |
|
|
2020
Q2 | $186K | Buy |
+805
| New | +$186K | ﹤0.01% | 1951 |
|
|
2019
Q4 | – | Sell |
-565
| Closed | -$109K | – | 2325 |
|
|
2019
Q3 | $109K | Buy |
+565
| New | +$109K | ﹤0.01% | 2287 |
|